Literature DB >> 9851321

Nosocomial wound infections: a prevalence study and analysis of risk factors.

N Wischnewski1, G Kampf, P Gastmeier, J Schlingmann, M Schumacher, F Daschner, H Ruden.   

Abstract

This first German prevalence study surveilling nosocomial wound infections (NWI) was carried out in 72 representatively selected hospitals. NWI were recorded by 4 validated investigators. Seventy-nine NWI were recorded among 4983 operated patients (prevalence rate: 1.61%), most of them after amputation of limbs (6.1%) and operations on the colon or rectum (3.1%). The 3 risk factors from the NNIS (National Nosocomial Infection Surveillance) index for postoperative wound infections were for the first time applied in this prevalence study. Patients with contaminated wounds had significantly more wound infections (P=0.01, likelihood ratio test) whereas, in contrast to the NNIS index, patients with ASA score >3 (P= 0.07) or long lasting operations (>75th percentile) did not (P=0.1). Therefore, for the stratification of NWI rates wound contamination is the single most important factor.

Entities:  

Mesh:

Year:  1998        PMID: 9851321

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  3 in total

1.  Does preoperative American Society of Anesthesiologists score relate to complications after total shoulder arthroplasty?

Authors:  Christine C Johnson; Sonal Sodha; Juan Garzon-Muvdi; Steve A Petersen; Edward G McFarland
Journal:  Clin Orthop Relat Res       Date:  2013-12-10       Impact factor: 4.176

2.  [Electronic surveillance of nosocomial infections in head and neck surgery and stapes surgery].

Authors:  S Preyer; A Failenschmid; M Holderried; D Bless
Journal:  HNO       Date:  2005-04       Impact factor: 1.284

3.  Prevalence and root causes of surgical site infection among women undergoing caesarean section in Ethiopia: a systematic review and meta-analysis.

Authors:  Fentahun Adane; Abay Mulu; Girma Seyoum; Alemu Gebrie; Akilog Lake
Journal:  Patient Saf Surg       Date:  2019-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.